Dan Brennan, a senior analyst at TD Cowen, discussed promising stocks in the life-sciences sector, particularly focusing on cancer diagnostics, precision medicine, and research tools. He highlighted three key companies:
-
Guardant Health – A leader in blood-based cancer testing, Guardant is expanding into earlier cancer detection and multi-cancer screening, presenting a strong growth opportunity despite a recent stock pullback.
-
Caris Life Sciences – A competitor in the tissue diagnostics space, Caris has a robust tissue-testing franchise. Although their stock has underperformed compared to Guardant, Brennan believes their differential approach and growing pipeline hold significant future potential.
-
Thermo Fisher Scientific – A global life-science tools leader, Thermo Fisher caters to diverse markets, including pharmaceuticals and diagnostics. Brennan sees this as a prime investment opportunity due to its depressed valuation and the expectation of accelerating growth.
Overall, the sector is witnessing a rebound as demand and sentiment recover post-pandemic, with liquid biopsies and tissue diagnostics driving innovation.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.bnnbloomberg.ca/investing/hot-picks/2026/05/01/hot-picks-life-sciences-stocks-are-seen-poised-for-growth/
